Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HistoIndex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Tropifexor

    Menu

    Tropifexor

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HistoIndex

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in NASH

              Details:

              The data from the analysis further illustrates the significance of the AI-based digital pathology platform in revealing fibrosis regression in patients treated with Tropifexor (TXR) and its relation to steatosis (liver fat) reduction.

              Lead Product(s): Tropifexor

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LJN452

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Bora Pharmaceuticals- Making success more certain.
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY